According to the World Tourism Organization (UN Tourism) , international tourist arrivals in Asia-Pacific reached approximately 316 million in 2024 , reflecting strong recovery in medical and wellness tourism activities, which continues to drive demand for IV glutathione treatments across the region
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
Ive seen more than one heated debate on this topic
In a 10-week, double-blind, placebo-controlled trial, adjunctive riluzole (vs
In addition, we also observed significant changes in citrulline, N -carbamoyl-L-aspartate, thymine, S -adenosyl-L-methionine, homoserine, guanosine, nicotinamide ribotide, hydroxyproline, succinate, cystathionine, aspartate, uridine, acetyl-L-lysine, and dimethyl-L-arginine (Figure 9, B and C, and Supplemental Figure 7B)
